AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

On National HIV Testing Day, getting tested remains a gateway to prevention and treatment, but improving access alone is not enough. Expanding access to PrEP, PEP, pharmacists, long-acting therapies, ...

Recent data from the National Cancer Institute (NCI) suggest that the number of people in the US diagnosed with diffuse large ...

National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...

Interrupted time-series signals showed exacerbations increased before 2015 but dropped sharply after 2015 and continued ...